trk in 4

Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor with IC50 = 1.1~2.6 nM for TrkA TrkB TrkC and antinociceptive effects. It is also a selective type II PTK6 inhibitor with IC50 = 76 nM and has antitumor effects.

PF-06273340 is an effective, Selective, and Peripherally Restricted Pan-Trk inhibitor (IC50: Trk-A = 6 nM; Trk-B = 4 nM; Trk-C = 3 nM). PF-06273340 has low metabolic turnover in HLM and hHep is a good substrate for efflux transporters P-gp (ER = 35.7) and BCRP (ER = 4.0) and has moderate passive permeability (RRCK Papp = 5.4 × 10 6 cm s 1).

TRK-IN-17 is a potent inhibitor of TRK, specifically targeting tropomyosin-related kinase (Trk), a receptor tyrosine kinase activated by neurotrophic factors, which include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophic factor-3 (NT-3), and neurotrophic factor-4 5 (NT-4 5). TRK-IN-17 has potential for cancer disease research.

TRK-IN-18 is a potent inhibitor of TRK, a family of receptor tyrosine kinases (Trks) activated by neurotrophic factors, which include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophic factor-3 (NT-3), and neurotrophic factor-4 5 (NT-4 5). 18 exhibits potential for the study of cancer diseases.